| March 29, 2004 | |||||||||
In Print![]() Photo by Steve Gilbert
From Focus: As the first FDA-approved anti-angiogenesis drug hit the market in February, Harvard researchers described advances in targeting tumor angiogenesis to fight cancer. Judah Folkman (on right) and colleagues have revamped a discarded angiogenesis inhibitor, setting it on a path back to the clinic. And Rakesh Jain (on left) and collaborators have observed the workings of the angiogenesis inhibitor that recently earned FDA approval.
|
|
HeadlinesNewly Identified Gene Linked to Brain Development Key Advance Reported in Regenerating Nerve Fibers New Tumor Suppressor May Play Important Role in Deadly Brain Tumors Study Details Brain Changes in Autism, Language Disorder Activity of Calcium-handling Gene Appears to Prevent Cardiac Arrhythmias
UpcomingElectronic Site Licenses to Academic Journals: A Boon for Whom?
Carl Bergstrom, University of Washington |
Spotlight
Student Scene
Lab WorksA multimedia site featuring Harvard Medical research |
||||||
Calendar | Jobs | Harvard Medical School Home | Hospitals | Back Issues | Feedback | Home |